Advanced search
Publication Cover
Expert Review of Medical Devices Volume 10, 2013 - Issue 4
Submit an article Journal homepage
103
Views
3
CrossRef citations to date
0
Altmetric
Perspective

The copper intrauterine device for emergency contraception: an opportunity to provide the optimal emergency contraception method and transition to highly effective contraception

Amna I Dermish Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT, USA
&
David K Turok Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT, USA. [email protected]
Pages 477-488 | Published online: 09 Jan 2014

References

  • Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception 84(5), 478–485 (2011).
  • Singh S, Sedgh G, Hussain R. Unintended pregnancy: worldwide levels, trends, and outcomes. Stud. Fam. Plann. 41(4), 241–250 (2010).
  • Sedgh G, Singh S, Shah IH, Ahman E, Henshaw SK, Bankole A. Induced abortion: incidence and trends worldwide from 1995 to 2008. Lancet 379(9816), 625–632 (2012).
  • Shah PS, Balkhair T, Ohlsson A, Beyene J, Scott F, Frick C. Intention to become pregnant and low birth weight and preterm birth: a systematic review. Matern. Child Health J. 15(2), 205–216 (2011).
  • Mohllajee AP, Curtis KM, Morrow B, Marchbanks PA. Pregnancy intention and its relationship to birth and maternal outcomes. Obstet. Gynecol. 109(3), 678–686 (2007).
  • Messer LC, Dole N, Kaufman JS, Savitz DA. Pregnancy intendedness, maternal psychosocial factors and preterm birth. Matern. Child Health J. 9(4), 403–412 (2005).
  • Marston C, Cleland J. Do unintended pregnancies carried to term lead to adverse outcomes for mother and child? An assessment in five developing countries. Popul. Stud. (Camb.) 57(1), 77–93 (2003).
  • Monea E, Thomas A. Unintended pregnancy and taxpayer spending. Perspect. Sex. Reprod. Health 43(2), 88–93 (2011).
  • Sonfield A, Kost K, Gold RB, Finer LB. The public costs of births resulting from unintended pregnancies: national and state-level estimates. Perspect. Sex. Reprod. Health 43(2), 94–102 (2011).
  • Trussell J. The cost of unintended pregnancy in the United States. Contraception 75(3), 168–170 (2007).
  • Trussell J, Henry N, Hassan F, Prezioso A, Law A, Filonenko A. Burden of unintended pregnancy in the United States: potential savings with increased use of long-acting reversible contraception. Contraception 87(2), 154–161 (2013).
  • Trussell J, Guthrie K. Choosing a contraceptive: efficacy, safety, and personal considerations. In: Contraceptive Technology. Ardent Media, Inc., NY, USA, 45–74 (2011).
  • Trussell J, Schwarz EB, Guthrie K. Research priorities for preventing unintended pregnancy: moving beyond emergency contraceptive pills. Perspect. Sex. Reprod. Health 42(1), 8–9 (2010).
  • Grimes DA. Forgettable contraception. Contraception 80(6), 497–499 (2009).
  • Secura GM, Allsworth JE, Madden T, Mullersman JL, Peipert JF. The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception. Am. J. Obstet. Gynecol. 203(2), 115.e1–115.e7 (2010).
  • Peipert JF, Zhao Q, Allsworth JE et al. Continuation and satisfaction of reversible contraception. Obstet. Gynecol. 117(5), 1105–1113 (2011).
  • Winner B, Peipert JF, Zhao Q et al. Effectiveness of long-acting reversible contraception. N. Engl. J. Med. 366(21), 1998–2007 (2012).
  • Peipert JF, Madden T, Allsworth JE, Secura GM. Preventing unintended pregnancies by providing no-cost contraception. Obstet. Gynecol. 120(6), 1291–1297 (2012).
  • Creinin MD, Schlaff W, Archer DF et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet. Gynecol. 108(5), 1089–1097 (2006).
  • Fine P, Mathé H, Ginde S, Cullins V, Morfesis J, Gainer E. Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception. Obstet. Gynecol. 115(2 Pt 1), 257–263 (2010).
  • Glasier AF, Cameron ST, Fine PM et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet 375(9714), 555–562 (2010).
  • von Hertzen H, Piaggio G, Ding J et al.; WHO Research Group on Post-ovulatory Methods of Fertility Regulation. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 360(9348), 1803–1810 (2002).
  • von Hertzen H, Piaggio G, Van Look PF. Emergency contraception with levonorgestrel or the Yuzpe regimen. Task Force on Postovulatory Methods of Fertility Regulation. Lancet 352(9144), 1939 (1998).
  • Piaggio G, Kapp N, von Hertzen H. Effect on pregnancy rates of the delay in the administration of levonorgestrel for emergency contraception: a combined analysis of four WHO trials. Contraception 84(1), 35–39 (2011).
  • Belzer M, Sanchez K, Olson J, Jacobs AM, Tucker D. Advance supply of emergency contraception: a randomized trial in adolescent mothers. J. Pediatr. Adolesc. Gynecol. 18(5), 347–354 (2005).
  • Ellertson C, Ambardekar S, Hedley A, Coyaji K, Trussell J, Blanchard K. Emergency contraception: randomized comparison of advance provision and information only. Obstet. Gynecol. 98(4), 570–575 (2001).
  • Glasier A, Baird D. The effects of self-administering emergency contraception. N. Engl. J. Med. 339(1), 1–4 (1998).
  • Gold MA, Wolford JE, Smith KA, Parker AM. The effects of advance provision of emergency contraception on adolescent women’s sexual and contraceptive behaviors. J. Pediatr. Adolesc. Gynecol. 17(2), 87–96 (2004).
  • Hazari K. Use of emergency contraception by women as a back-up method. Health Popul. Perspect. Issue. 23, 115–122 (2000).
  • Hu X, Cheng L, Hua X, Glasier A. Advanced provision of emergency contraception to postnatal women in China makes no difference in abortion rates: a randomized controlled trial. Contraception 72(2), 111–116 (2005).
  • Jackson RA, Schwarz EB, Freedman L, Darney P. Advance supply of emergency contraception. effect on use and usual contraception–a randomized trial. Obstet. Gynecol. 102(1), 8–16 (2003).
  • Lo SS, Fan SY, Ho PC, Glasier AF. Effect of advanced provision of emergency contraception on women’s contraceptive behaviour: a randomized controlled trial. Hum. Reprod. 19(10), 2404–2410 (2004).
  • Lovvorn A, Nerquaye-Tetteh J, Glover EK, Amankwah-Poku A, Hays M, Raymond E. Provision of emergency contraceptive pills to spermicide users in Ghana. Contraception 61(4), 287–293 (2000).
  • Raine T, Harper C, Leon K, Darney P. Emergency contraception: advance provision in a young, high-risk clinic population. Obstet. Gynecol. 96(1), 1–7 (2000).
  • Raine TR, Harper CC, Rocca CH et al. Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs: a randomized controlled trial. JAMA 293(1), 54–62 (2005).
  • Raymond EG, Stewart F, Weaver M, Monteith C, Van Der Pol B. Impact of increased access to emergency contraceptive pills: a randomized controlled trial. Obstet. Gynecol. 108(5), 1098–1106 (2006).
  • Skibiak J, Ahmed Y, Ketata M. Testing strategies to improve access to emergency contraception pills: prescription vs. prophylactic distribution. Nairobi Population Council (1999).
  • Walsh TL, Frezieres RG. Patterns of emergency contraception use by age and ethnicity from a randomized trial comparing advance provision and information only. Contraception 74(2), 110–117 (2006).
  • Baecher L, Weaver MA, Raymond EG. Increased access to emergency contraception: why it may fail. Hum. Reprod. 24(4), 815–819 (2009).
  • Raymond EG, Trussell J, Polis CB. Population effect of increased access to emergency contraceptive pills: a systematic review. Obstet. Gynecol. 109(1), 181–188 (2007).
  • Weaver MA, Raymond EG, Baecher L. Attitude and behavior effects in a randomized trial of increased access to emergency contraception. Obstet. Gynecol. 113(1), 107–116 (2009).
  • Polis CB, Schaffer K, Blanchard K, Glasier A, Harper CC, Grimes DA. Advance provision of emergency contraception for pregnancy prevention (full review). Cochrane Database Syst. Rev. 2, CD005497 (2007).
  • Glasier A, Cameron ST, Blithe D et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception 84(4), 363–367 (2011).
  • Noé G, Croxatto HB, Salvatierra AM et al. Contraceptive efficacy of emergency contraception with levonorgestrel given before or after ovulation. Contraception 84(5), 486–492 (2011).
  • Novikova N, Weisberg E, Stanczyk FZ, Croxatto HB, Fraser IS. Effectiveness of levonorgestrel emergency contraception given before or after ovulation – a pilot study. Contraception 75(2), 112–118 (2007).
  • Wilcox AJ, Dunson DB, Weinberg CR, Trussell J, Baird DD. Likelihood of conception with a single act of intercourse: providing benchmark rates for assessment of post-coital contraceptives. Contraception 63(4), 211–215 (2001).
  • Cameron ST, Glasier A, Johnstone A, Rae L. Ongoing contraception after use of emergency contraception from a specialist contraceptive service. Contraception 84(4), 368–371 (2011).
  • Lippes J, Malik T, Tatum HJ. The postcoital copper-T. Adv. Plan. Parent. 11(1), 24–29 (1976).
  • Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception 75(Suppl. 6), S16–S30 (2007).
  • ACOG Practice Bulletin No. 112. Emergency contraception. Obstet. Gynecol. 115(5), 1100–1109 (2010).
  • Devonald B. IUS as emergency contraception. J. Fam. Plann. Reprod. Health Care 35(3), 205; discussion 205–205; discussion 206 (2009).
  • Clinical Effectiveness Unit. Emergency Contraception Guidance. Faculty of 604 Sexual and Reproductive Health, London, UK. (2012).
  • WHO. Selected Practice Recommendations for Contraceptive Use. WHO, Geneva, Switzerland, 67–70 (2004).
  • US Medical Eligibility Criteria for Contraceptive Use, 2010. US Medical Eligibility Criteria for Contraceptive Use, 2010, 59(RR-4), 1–86 (2010).
  • Faculty of Sexual and Reproductive Healthcare. UK Medical Eligibility Criteria for Contraceptive Use. UK Medical Eligibility Criteria for Contraceptive Use (2009).
  • Wu S, Godfrey EM, Wojdyla D et al. Copper T380A intrauterine device for emergency contraception: a prospective, multicentre, cohort clinical trial. BJOG 117(10), 1205–1210 (2010).
  • Zhou L, Xiao B. Emergency contraception with Multiload Cu-375 SL IUD: a multicenter clinical trial. Contraception 64(2), 107–112 (2001).
  • Cleland K, Zhu H, Goldstuck N, Cheng L, Trussell J. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum. Reprod. 27(7), 1994–2000 (2012).
  • Sivin I, el Mahgoub S, McCarthy T et al. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study. Contraception 42(4), 361–378 (1990).
  • Turok D, Jacobson J, Dermish A, Simonsen S, Horn JT-V, Murphy P. Pregnancy rates 1 year after choosing the copper T380 IUD or oral levonorgestrel for emergency contraception: a prospective observational study [abstract]. Contraception 86(3), 294 (2012).
  • WHO. Intrauterine Devices: Medical Eligibility Criteria for Contraceptive Use. WHO, Geneva, Switzerland, 65–70 (2009).
  • Dean G, Schwarz E. Intrauterine contraceptives (IUCs). In: Contraceptive Technology. Ardent Media, Inc., 147–192 (2011).
  • Caliskan E, Oztürk N, Dilbaz BO, Dilbaz S. Analysis of risk factors associated with uterine perforation by intrauterine devices. Eur. J. Contracept. Reprod. Health Care 8(3), 150–155 (2003).
  • Kaislasuo J, Suhonen S, Gissler M, Lähteenmäki P, Heikinheimo O. Intrauterine contraception: incidence and factors associated with uterine perforation–a population-based study. Hum. Reprod. 27(9), 2658–2663 (2012).
  • Hubacher D. Copper intrauterine device use by nulliparous women: review of side effects. Contraception 75(Suppl. 6), S8–11 (2007).
  • Garbers S, Haines-Stephan J, Lipton Y, Meserve A, Spieler L, Chiasson MA. Continuation of copper-containing intrauterine devices at 6 months. Contraception 87(1), 101–106 (2013).
  • Hubacher D, Cheng D. Intrauterine devices and reproductive health: American women in feast and famine. Contraception 69(6), 437–446 (2004).
  • d’Arcangues C. Worldwide use of intrauterine devices for contraception. Contraception 75(Suppl. 6), S2–S7 (2007).
  • Gutin SA, Mlobeli R, Moss M, Buga G, Morroni C. Survey of knowledge, attitudes and practices surrounding the intrauterine device in South Africa. Contraception 83(2), 145–150 (2011).
  • van Zijl S, Morroni C, van der Spuy ZM. A survey to assess knowledge and acceptability of the intrauterine device in the Family Planning Services in Cape Town, South Africa. J. Fam. Plann. Reprod. Health Care 36(2), 73–78 (2010).
  • ACOG Committee Opinion No. 450. Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet. Gynecol. 114(6), 1434–1438 (2009).
  • Committee Opinion No. 539. Adolescents and long-acting reversible contraception: implants and intrauterine devices. Obstet. Gynecol. 120(4), 983–988 (2012).
  • McNicholas C, Hotchkiss T, Madden T, Zhao Q, Allsworth J, Peipert JF. Immediate postabortion intrauterine device insertion: continuation and satisfaction. Womens. Health Issues 22(4), e365–e369 (2012).
  • Finer LB, Jerman J, Kavanaugh ML. Changes in use of long-acting contraceptive methods in the United States, 2007-2009. Fertil. Steril. 98(4), 893–897 (2012).
  • Lyus R, Lohr P, Prager S; Board of the Society of Family Planning. Use of the Mirena LNG-IUS and Paragard CuT380A intrauterine devices in nulliparous women. Contraception 81(5), 367–371 (2010).
  • Meirik O. Intrauterine devices - upper and lower genital tract infections. Contraception 75(Suppl. 6), S41–S47 (2007).
  • Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception 73(2), 145–153 (2006).
  • Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 339(8796), 785–788 (1992).
  • Al-Tayyib AA, Miller WC, Rogers SM et al. Evaluation of risk score algorithms for detection of chlamydial and gonococcal infections in an emergency department setting. Acad. Emerg. Med. 15(2), 126–135 (2008).
  • Morrison CS, Murphy L, Kwok C, Weiner DH. Identifying appropriate IUD candidates in areas with high prevalence of sexually transmitted infections. Contraception 75(3), 185–192 (2007).
  • Rugpao S, Rungruengthanakit K, Werawatanakul Y et al. Risk factors and algorithms for chlamydial and gonococcal cervical infections in women attending family planning clinics in Thailand. J. Obstet. Gynaecol. Res. 36(1), 147–153 (2010).
  • Murphy PA, Jacobson J, Turok DK. Criterion-based screening for sexually transmitted infection: sensitivity, specificity, and predictive values of commonly used questions. J. Midwifery Womens. Health 57(6), 622–628 (2012).
  • Leeman L. Medical barriers to effective contraception. Obstet. Gynecol. Clin. North Am. 34(1), 19–29, vii (2007).
  • Sufrin CB, Postlethwaite D, Armstrong MA, Merchant M, Wendt JM, Steinauer JE. Neisseria gonorrhea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease. Obstet. Gynecol. 120(6), 1314–1321 (2012).
  • Tepper NK, Steenland MW, Gaffield ME, Marchbanks PA, Curtis KM. Retention of intrauterine devices in women who acquire pelvic inflammatory disease: a systematic review. Contraception (2012).
  • Morrison CS, Sekadde-Kigondu C, Sinei SK, Weiner DH, Kwok C, Kokonya D. Is the intrauterine device appropriate contraception for HIV-1-infected women? BJOG 108(8), 784–790 (2001).
  • Sinei SK, Morrison CS, Sekadde-Kigondu C, Allen M, Kokonya D. Complications of use of intrauterine devices among HIV-1-infected women. Lancet 351(9111), 1238–1241 (1998).
  • Richardson BA, Morrison CS, Sekadde-Kigondu C et al. Effect of intrauterine device use on cervical shedding of HIV-1 DNA. AIDS 13(15), 2091–2097 (1999).
  • Stringer EM, Kaseba C, Levy J et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am. J. Obstet. Gynecol. 197(2), 144.e1–144.e8 (2007).
  • Grimes DA, Schulz KF. Prophylactic antibiotics for intrauterine device insertion: a metaanalysis of the randomized controlled trials. Contraception 60(2), 57–63 (1999).
  • Skjeldestad FE. The impact of intrauterine devices on subsequent fertility. Curr. Opin. Obstet. Gynecol. 20(3), 275–280 (2008).
  • Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzmán-Rodríguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N. Engl. J. Med. 345(8), 561–567 (2001).
  • Turok DK, Gurtcheff SE, Handley E et al. A survey of women obtaining emergency contraception: are they interested in using the copper IUD? Contraception 83(5), 441–446 (2011).
  • Schwarz EB, Kavanaugh M, Douglas E, Dubowitz T, Creinin MD. Interest in intrauterine contraception among seekers of emergency contraception and pregnancy testing. Obstet. Gynecol. 113(4), 833–839 (2009).
  • Turok DK, Gurtcheff SE, Handley E, Simonsen SE, Sok C, Murphy P. A pilot study of the Copper T380A IUD and oral levonorgestrel for emergency contraception. Contraception 82(6), 520–525 (2010).
  • Dermish AI, Turok DK, Jacobson JC, Flores ME, McFadden M, Burke K. Failed IUD insertions in community practice: an under-recognized problem? Contraception 87(2), 182–186 (2013).
  • Dermish A, Turok D, Kim J. Cost–effectiveness of emergency contraception: IUDs vs. oral EC [abstract]. Contraception 86(3) (2012).
  • Allen RH, Goldberg AB, Grimes DA. Expanding access to intrauterine contraception. Am. J. Obstet. Gynecol. 201(5), 456.e1–456.e5 (2009).
  • Bharadwaj P, Saxton JC, Mann SN, Jungmann EM, Stephenson JM. What influences young women to choose between the emergency contraceptive pill and an intrauterine device? A qualitative study. Eur. J. Contracept. Reprod. Health Care 16(3), 201–209 (2011).
  • Wright RL, Frost CJ, Turok DK. A qualitative exploration of emergency contraception users’ willingness to select the copper IUD. Contraception 85(1), 32–35 (2012).
  • Harper CC, Speidel JJ, Drey EA, Trussell J, Blum M, Darney PD. Copper intrauterine device for emergency contraception: clinical practice among contraceptive providers. Obstet. Gynecol. 119(2 Pt 1), 220–226 (2012).
  • Harper CC, Blum M, de Bocanegra HT et al. Challenges in translating evidence to practice: the provision of intrauterine contraception. Obstet. Gynecol. 111(6), 1359–1369 (2008).
  • Harper CC, Henderson JT, Raine TR et al. Evidence-based IUD practice: family physicians and obstetrician-gynecologists. Fam. Med. 44(9), 637–645 (2012).
  • ACOG Practice Bulletin No. 121. Long-acting reversible contraception: implants and intrauterine devices. Obstet. Gynecol. 118(1), 184–196 (2011).
  • Blythe MJ, Diaz A. Contraception and adolescents. Pediatrics 120(5), 1135–1148 (2007).
  • Belden P, Harper CC, Speidel JJ. The copper IUD for emergency contraception, a neglected option. Contraception 85(4), 338–339 (2012).
  • Bahamondes MV, Hidalgo MM, Bahamondes L, Monteiro I. Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas. Contraception 84(5), e11–e16 (2011).
  • Brockmeyer A, Kishen M, Webb A. Experience of IUD/IUS insertions and clinical performance in nulliparous women–a pilot study. Eur. J. Contracept. Reprod. Health Care 13(3), 248–254 (2008).
  • Farmer M, Webb A. Intrauterine device insertion-related complications: can they be predicted? J. Fam. Plann. Reprod. Health Care 29(4), 227–231 (2003).
  • Farr G, Rivera R, Amatya R. Non-physician insertion of IUDs: clinical outcomes among TCu380A insertions in three developing-country clinics. Adv. Contracept. 14(1), 45–57 (1998).
  • Lassner KJ, Chen CH, Kropsch LA, Oberle MW, Lopes IM, Morris L. Comparative study of safety and efficacy of IUD insertions by physicians and nursing personnel in Brazil. Bull. Pan Am. Health Organ. 29(3), 206–215 (1995).
  • Murty J. Use and effectiveness of oral analgesia when fitting an intrauterine device. J. Fam. Plann. Reprod. Health Care 29(3), 150–151 (2003).
  • Bergin A, Tristan S, Terplan M, Gilliam ML, Whitaker AK. A missed opportunity for care: two-visit IUD insertion protocols inhibit placement. Contraception 86(6), 694–697 (2012).
  • Cheng L, Gülmezoglu AM, Piaggio G, Ezcurra E, Van Look PF. Interventions for emergency contraception. Cochrane Database Syst. Rev. 2, CD001324 (2008).
  • Trussell J, Schwarz E. Emergency contraception. In: Contraceptive Technology. Ardent Media, Inc., 113–146 (2011).
  • Turok D, Godfrey EM, Wojdyla D et al. Copper T380 IUD for EC: highly effective at any time in the menstrual cycle [abstract]. Contraception 86(6), 773 (2012).
  • Dermish A, Jacobson J, Murphy P, Torres L, Turok D, Ward K. Oral LNG vs copper T380 IUD: understanding use of EC in relation to timing from LMP [abstract]. Contraception 86(3), 177 (2012).
  • Trussell J, Stewart F, Guest F, Hatcher RA. Emergency contraceptive pills: a simple proposal to reduce unintended pregnancies. Fam. Plann. Perspect. 24(6), 269–273 (1992).
  • Whitaker AK, Johnson LM, Harwood B, Chiappetta L, Creinin MD, Gold MA. Adolescent and young adult women’s knowledge of and attitudes toward the intrauterine device. Contraception 78(3), 211–217 (2008).
  • Dehlendorf C, Levy K, Ruskin R, Steinauer J. Health care providers’ knowledge about contraceptive evidence: a barrier to quality family planning care? Contraception 81(4), 292–298 (2010).
  • Access to emergency contraception. Obstet. Gynecol. 120(5), 1250–1253 (2012).
  • Rapkin R, Creinin M. When it comes to the morning-after pill, physicians need a wake-up call. OBG Management 23(8), 22–24 (2011).
  • Lippes J, Tatum H, Maulik D, Zilezny M. Postcoital copper IUDs. Adv. Plann. Parent 14, 87–94 (1979).
  • Black TR, Goldstuck ND, Spence A. Post-coital intrauterine device insertion – a further evaluation. Contraception 22(6), 653–658 (1980).
  • Goldstuck ND. Delayed postcoital IUD insertion. Contracept. Deliv. Syst. 4(4), 293–296 (1983).
  • Gottardi G, Spreafico A, de Orchi L. The postcoital IUD as an effective continuing contraceptive method. Contraception 34(6), 549–558 (1986).
  • Luerti M, Tonta A, Ferla P, Molla R, Santini F. Post-coital contraception by estrogen/progestogen combination or IUD insertion. Contraception 33(1), 61–68 (1986).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.